Brainstorm announces topline results from nurown® phase 3 als study

New york, nov. 17, 2020 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the company's randomized, double-blind placebo-controlled phase 3 trial...
BCLI Ratings Summary
BCLI Quant Ranking